LPCN -71% on CRL for oral testosterone: https://www.prnewswire.com/news-releases/lipocine-receives-complete-response-letter-for-tlando-from-us-fda-300955195.html The CRL identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations ("Cmax"). Ouch.